AMYLIN PHARM. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMYLIN PHARM.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: luis a. garcia who wrote (40)	9/25/1997 8:17:00 AM
From: the Chief	of 52

California Technology Stock Letter!!!! This stock letter submitted the folowing article to the "Investor's Digest" September 26 1997 issue. "This advisory continues to beat the drum for Amylin (AMLN-NASDAQ,$8) which plunged 40 percent last month on news that early trials for its glucose control drug Pramlintide were not going so well. The advisory says the price seems to be stabilizing at $8. "This is a bargain". It says the chairman of the company agrees and he's just stepped up to add 10,000 shares to his personal portfolio. "We don't expect the stock to stay here until the company has results from the currently on-going trials next fall", the advisory adds. "Investors will begin to understand the positive subgroup results in the just released data and why that increases the chances for success in the other four pivotal trials now underway. Take advantage of the weakness and buy more here for a long term target of $100." Long term $100, seems like a good return to me, and I'm not a rocket scientist!!!! Please comment the Chief

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next